Paediatric drug formulations for poverty-related diseases – 2019
Funding under this call aims to support research on the adaptation of existing medicinal products (drugs), including off-patent products, to the specific needs of children (0-17 years of age) for any poverty-related disease within the scope of the EDCTP2 programme. Proposals were to include one (or more) clinical trials conducted in sub-Saharan Africa to assess the safety, efficacy and pharmacokinetics of the drug(s), and/or the development of age-appropriate formulations.
Towards a pediatric indication for children between 1 and 14 years of age for a safe, effective, all-oral single-dose treatment formulation of acoziborole for first and second stage gambiense human African trypanosomiasis (g-HAT)
Drugs for Neglected Diseases initiative, Geneva, Switzerland, with partners from the Democratic Republic of the Congo, France, Guinea, and Portugal Project coordinator: Dr Antoine Tarral Starting date: 01 October 2020 Duration: 60 months EDCTP grant amount: EUR 2,999,107 Grant agreement: RIA2019PD-2890
Developing paediatric primaquine
Chancellor, Masters and Scholars of the University of Oxford, Oxford, United Kingdom, with partners from Burkina Faso, Ethiopia, and France Project coordinator: Dr W.R.J. Taylor Starting date: 01 September 2020 Duration: 56 months EDCTP grant amount: EUR 3,489,896 Grant agreement: RIA2019PD-2893 Project website
Treatment for all: Developing a paediatric formulation moxidectin for neglected infectious diseases
Luxembourg Institute of Health, Luxembourg, Luxembourg, with partners from Cameroon, Germany, Ghana, and the United Kingdom Project coordinator: Dr Michel Vaillant Starting date: 01 January 2021 Duration: 42 months EDCTP grant amount: EUR 2,112,690 Grant agreement: RIA2019PD-2880